1. Radioligand (choose only one):

DaTSCAN

Altropane

β-CIT

FDG

Florbetapir

Florbetaben

Florbetamol

PIB

DOPA

MIBG

Fluoro-metatyrosine (FMT)

2-deoxy-glucose (either C14 or H3)

Other, specify:

1. Specific activity of radioligand:

(Bq/kg):

Not Known

1. Isotope:

123-I

18-F

11-C

99 Tcm

Other, specify:

1. Camera (include Type of scanner and Manufacturer):

Siemens Symphony

Siemens Trio

Phillips Achieva

GE Signa

Other, specify:

1. Camera Software:
2. Dose:

mCi

Mbq

Other, specify:

1. Time from Injection to Scan (minutes):
2. Duration of Scan (minutes):
3. Image Matrix Size:

64 X 64

128 X 128

512 X 512

Other, specify:

1. Slice Thickness (mm):
2. Pre-Scan action(s):

Lugols

Perchlorate

Withhold medication(s)

Limit sensory stimulation

Other, specify:

1. Parkinson’s Disease Medication(s) Status – Pre-treatment:

All medications withheld

If so, how long were they withheld?:

Days  Hours  Minutes

Specific medications(s) withheld

If so, list the medications that were withheld and how long they were withheld:

1:Duration Withheld Table

| Parkinson’s Disease (PD) Medication | Duration Withheld |
| --- | --- |
| Data to be entered by site. | Days  Hours  Minutes |
| Data to be entered by site. | Days  Hours  Minutes |
| Data to be entered by site. | Days  Hours  Minutes |

No medications(s) withheld

1. Current Body Weight (kg):
2. Post Injection Management prior to scan:

No special management required

Quiet room

Eyes open

Other, specify:

1. Reconstruction of raw data:

Iterative  Filtered back projection  Other, specify:

1. Attenuation Correction:

Homogenous

Inhomogenous

Other, specify:

1. Post Reconstruction Filter:

Butterworth

Lowpass

Gaussian

Other, specify:

1. Visual Analysis

Normal

Abnormal

Other, specify:

1. Where visual analysis performed

Site

Central

Other, specify:

1. Was where the visual analysis performed blinded to clinical data?

Yes

No

Unknown

Other, specify:

1. Imaging outcome

Volume of interest

Voxel based

Other, specify:

1. Method for VOI placement:

Automated

Subjective Placement

Other, specify:

1. VOI Locations

Striatum

Cortex

Other, specify:

1. Reference Region:
2. Quantitative Imaging Outcome:

DAT Scan

Altropane

β-CIT

Fluoro-metatyrosine (FMT)

FDopa

Striatal (Regional) Binding Ratios:

Putamen Binding Ratio:

Caudate Binding Ratio:

Other, specify:

Amyloid Imaging Standard Uptake Value (SUV)

Neocortex:

Posterior cingual/precuneus:

Frontal:

Parietal:

Lateral:

Temporal:

Mesiotemporal:

Anterior cingulate:

Striatum:

Cerebellar gray:

Whole cerebellum:

Other, specify:

Scan aborted, if checked, explain why:

Other, specify:

## General Instructions

This CRF contains data that would be collected when an imaging study is performed to measure cellular/tissue change. The data recorded assess the rate of absorption of radionuclides in healthy and diseased tissue, as tissue undergoing a disease process will absorb at a different rate.

Important note: None of the data elements included on this CRF Module is classified as Core (i.e., strongly recommended for Parkinson’s disease clinical studies to collect if imaging studies are performed). All data elements are classified as supplemental (i.e., non Core) and should only be collected if the research team considers them appropriate for their study. Please see the Data Dictionary for element classifications.

## Specific Instructions

Please see the Data Dictionary for definitions for each of the data elements included in this CRF Module.

The CRF includes all instructions available for the data elements at this time. More detailed instructions will be added in Version 2.0 of this CRF Module.